Vaccines & Viral Infectivity
In just under a century, the study of viruses and vaccines has advanced from experiments in primary cell culture to a worldwide industry that develops and produces some of the most effective tools in medicine. Modern vaccine production is generally accomplished using live viruses throughout the research, development and manufacturing processes. At each of these stages, analytical monitoring of viral infection is important to help ensure predictable infection and expansion, maximum yield, and safety parameters, especially for cell culture based processes. The current crop of viral infectivity assays are slow, expensive, and labor intensive, which increases the time and cost to produce vaccines. Other methods including quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA) can be faster but rely on specific molecules that are often expensive and time-consuming to produce, especially when adapting tests to novel or altered targets. Variations in vaccine storage time, temperature, or formulation can also affect the number of infectious particles in a sample necessitating the need for infectivity studies.
LumaCyte's Radiance instrument can be used for monitoring the infectivity of live and attenuated viruses both during and after production. Both R&D and manufacturing departments benefit from the rapid and accurate detection of viral titers. Radiance can also be used to verify that a virus has been properly killed or inactivated by demonstrating a lack of infectivity.
Some vaccines are manufactured using viral vectors such as adenovirus. Incorporating additional genes in these vectors can result in poor infectivity rendering it ineffective for drug or vaccine development. Radiance can quickly assess the infectivity of recombinant adenovirus in less than 24 hours of incubation with the target cells. Production can be monitored using Radiance via sequential aliquots or through continuous monitoring of the infection and production process.